Resolvins and protectins: Natural pharmacophores for resolution biology

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 82, Issue 4-6, 2010, Pages 327-332

  Levy, Bruce D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CD59 ANTIGEN; DEXAMETHASONE; DOCOSAHEXAENOIC ACID; FATTY ACID DERIVATIVE; FISH OIL; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; RESOLVIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; ASTHMA; COLITIS; DIETARY INTAKE; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; HUMAN; KIDNEY ISCHEMIA; LOW DRUG DOSE; MOLECULAR MECHANICS; MUCOSA INFLAMMATION; NEUROPROTECTION; NONHUMAN; PERIODONTITIS; PERITONITIS; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REPERFUSION INJURY; SKIN INFLAMMATION; SKIN INJURY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIGENS, CD59; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HUMANS; INFLAMMATION; MOLECULAR STRUCTURE;

EID: 77952105540     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2010.02.003     Document Type: Article

References (47)

1. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8:349-361.
2. Serhan C.N., Savill J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005, 6:1191-1197.
3. Serhan C.N. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 2007, 25:101-137.
4. Fukunaga K., Kohli P., Bonnans C., Fredenburgh L.E., Levy B.D. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J. Immunol. 2005, 174:5033-5039.
5. Schwab J.M., Chiang N., Arita M., Serhan C.N. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007, 447:869-874.
6. Celik G.E., Erkekol F.O., Misirligil Z., Melli M. Lipoxin A4 levels in asthma: relation with disease severity and aspirin sensitivity. Clin. Exp. Allergy 2007, 37:1494-1501.
7. Karp C.L., Flick L.M., Park K.W., et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 2004, 5:388-392.
8. Levy B.D., Bonnans C., Silverman E.S., et al. Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 2005, 172:824-830.
9. Planaguma A., Kazani S., Marigowda G., et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am. J. Respir. Crit. Care Med. 2008, 178:574-582.
10. Tahan F., Saraymen R., Gumus H. The role of lipoxin A4 in exercise-induced bronchoconstriction in asthma. J. Asthma 2008, 45:161-164.
11. Vachier I., Bonnans C., Chavis C., et al. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J. Allergy Clin. Immunol. 2005, 115:55-60.
12. Cotran R.V.K., Collins.T. Robbins Pathologic Basis of Disease 1999, Saunders, Philadelphia.
13. Haslett C. Resolution of acute inflammation and the role of apoptosis in the tissue fate of granulocytes. Clin. Sci. (London) 1992, 83:639-648.
14. Rossi A.G., Sawatzky D.A., Walker A., et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 2006, 12:1056-1064.
15. Savill J.S., Wyllie A.H., Henson J.E., Walport M.J., Henson P.M., Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J. Clin. Invest. 1989, 83:865-875.
16. Uller L., Persson C.G., Erjefalt J.S. Resolution of airway disease: removal of inflammatory cells through apoptosis, egression or both?. Trends Pharmacol. Sci. 2006, 27:461-466.
17. Godson C., Mitchell S., Harvey K., Petasis N.A., Hogg N., Brady H.R. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 2000, 164:1663-1667.
18. Campbell E.L., Louis N.A., Tomassetti S.E., et al. Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution. FASEB J. 2007, 21:3162-3170.
19. Bannenberg G.L., Chiang N., Ariel A., et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 2005, 174:4345-4355.
20. Levy B.D., Clish C.B., Schmidt B., Gronert K., Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2001, 2:612-619.
21. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 2000, 192:1197-1204.
22. Serhan C.N., Hong S., Gronert K., et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 2002, 196:1025-1037.
23. Arita M., Bianchini F., Aliberti J., et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 2005, 201:713-722.
24. Hong S., Gronert K., Devchand P.R., Moussignac R.L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 2003, 278:14677-14687.
25. Serhan C.N., Gotlinger K., Hong S., et al. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J. Immunol. 2006, 176:1848-1859.
26. Sun Y.P., Oh S.F., Uddin J., et al. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 2007, 282:9323-9334.
27. Arita M., Ohira T., Sun Y.P., Elangovan S., Chiang N., Serhan C.N. Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J. Immunol. 2007, 178:3912-3917.
28. Gronert K., Kantarci A., Levy B.D., et al. A molecular defect in intracellular lipid signaling in human neutrophils in localized aggressive periodontal tissue damage. J. Immunol. 2004, 172:1856-1861.
29. Haworth O., Cernadas M., Yang R., Serhan C.N., Levy B.D. Resolvin E1 regulates interleukin 23, interferon-gamma and lipoxin A(4) to promote the resolution of allergic airway inflammation. Nat. Immunol. 2008.
30. Ariel A., Fredman G., Sun Y.P., et al. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nat. Immunol. 2006, 7:1209-1216.
31. Hasturk H., Kantarci A., Ohira T., et al. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J. 2006, 20:401-403.
32. Hasturk H., Kantarci A., Goguet-Surmenian E., et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J. Immunol. 2007, 179:7021-7029.
33. Arita M., Yoshida M., Hong S., et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 2005, 102:7671-7676.
34. Gronert K., Maheshwari N., Khan N., Hassan I.R., Dunn M., Laniado Schwartzman M. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J. Biol. Chem. 2005, 280:15267-15278.
35. Arita M., Oh S.F., Chonan T., et al. Metabolic inactivation of resolvin E1 and stabilization of its anti-inflammatory actions. J. Biol. Chem. 2006, 281:22847-22854.
36. Cash J.L., Hart R., Russ A., et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 2008, 205:767-775.
37. Perretti M., Chiang N., La M., et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat. Med. 2002, 8:1296-1302.
38. Tjonahen E., Oh S.F., Siegelman J., et al. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 2006, 13:1193-1202.
39. Duffield J.S., Hong S., Vaidya V.S., Resolvin D., et al. Series and protectin D1 mitigate acute kidney injury. J. Immunol. 2006, 177:5902-5911.
40. Levy B.D., Kohli P., Gotlinger K., et al. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J. Immunol. 2007, 178:496-502.
41. Mukherjee P.K., Marcheselli V.L., Serhan C.N., Bazan N.G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc. Natl. Acad. Sci. USA 2004, 101:8491-8496.
42. Mukherjee P.K., Marcheselli V.L., Barreiro S., Hu J., Bok D., Bazan N.G. Neurotrophins enhance retinal pigment epithelial cell survival through neuroprotectin D1 signaling. Proc. Natl. Acad. Sci. USA 2007, 104:13152-13157.
43. Mukherjee P.K., Chawla A., Loayza M.S., Bazan N.G. Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77:233-238.
44. Marcheselli V.L., Hong S., Lukiw W.J., et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 2003, 278:43807-43817.
45. Lukiw W.J., Cui J.G., Marcheselli V.L., et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest. 2005, 115:2774-2783.
46. Ariel A., Li P.L., Wang W., et al. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J. Biol. Chem. 2005, 280:43079-43086.
47. Serhan C.N., Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br. J. Pharmacol. 2008, 153(Suppl. 1):S200-S215.